Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV-CHP?

Lancet Haematol

Hematology Department, Lyon Sud Hospital, Hospices Civils de Lyon, 69495 Piere Bénite, France; Lymphoma Immuno-Biology Research Unit, Inserm U1111, CIRI, Lyon, France. Electronic address:

Published: September 2024

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(24)00207-2DOI Listing

Publication Analysis

Top Keywords

etoposide addition
4
addition brentuximab
4
brentuximab vedotin
4
vedotin consolidation
4
consolidation first-line
4
first-line treatment
4
treatment cd30-positive
4
cd30-positive peripheral
4
peripheral t-cell
4
t-cell lymphoma
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!